211 related articles for article (PubMed ID: 27138730)
1. Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis.
Staubes BA; Metzger NL; Walker SD; Peasah SK
Pharmacotherapy; 2016 Jun; 36(6):623-30. PubMed ID: 27138730
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
Lam W; Tjon J; Seto W; Dekker A; Wong C; Atenafu E; Bitnun A; Waters V; Yau Y; Solomon M; Ratjen F
J Antimicrob Chemother; 2007 Jun; 59(6):1135-40. PubMed ID: 17446242
[TBL] [Abstract][Full Text] [Related]
3. Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring.
Stenbit AE; Bullington WM; Heh JL; Flume PA
J Cyst Fibros; 2013 Jul; 12(4):403-6. PubMed ID: 23266092
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM
J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357
[TBL] [Abstract][Full Text] [Related]
5. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
Prescott WA
Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
Vic P; Ategbo S; Turck D; Husson MO; Launay V; Loeuille GA; Sardet A; Deschildre A; Druon D; Arrouet-Lagande C
Arch Dis Child; 1998 Jun; 78(6):536-9. PubMed ID: 9713009
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis.
Brigg Turner R; Elbarbry F; Biondo L
J Chemother; 2016 Aug; 28(4):304-7. PubMed ID: 26430825
[TBL] [Abstract][Full Text] [Related]
8. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Al-Aloul M; Nazareth D; Walshaw M
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
[TBL] [Abstract][Full Text] [Related]
10. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
Hennig S; Norris R; Kirkpatrick CM
Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972
[TBL] [Abstract][Full Text] [Related]
11. [Serum level-adjusted dosage of once-daily aminoglycoside therapy in critical illness: results of a prospective study].
Reimann IR; Meier-Hellmann A; Pfeifer R; Traut T; Schilling A; Stein G; Reinhart K; Hoffmann A
Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 May; 34(5):288-95. PubMed ID: 10372218
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic target attainment with high-dose extended-interval tobramycin therapy in patients with cystic fibrosis.
DeGrado JR; Cios D; Greenwood BC; Kubiak DW; Szumita PM
J Chemother; 2014 Apr; 26(2):101-4. PubMed ID: 24090527
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
van Koningsbruggen-Rietschel S; Heuer HE; Merkel N; Posselt HG; Staab D; Sieder C; Ziegler J; Krippner F; Rietschel E
J Antimicrob Chemother; 2016 Mar; 71(3):711-7. PubMed ID: 26626719
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
Massie J; Cranswick N
J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
[TBL] [Abstract][Full Text] [Related]
16. Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation.
Walsh KA; Davis GA; Hayes D; Kuhn RJ; Weant KA; Flynn JD
Transpl Infect Dis; 2011 Dec; 13(6):616-21. PubMed ID: 21794042
[TBL] [Abstract][Full Text] [Related]
17. Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin.
Ruddy J; Emerson J; Moss R; Genatossio A; McNamara S; Burns JL; Anderson G; Rosenfeld M
J Aerosol Med Pulm Drug Deliv; 2013 Apr; 26(2):69-75. PubMed ID: 22620494
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis.
Hennig S; Standing JF; Staatz CE; Thomson AH
Clin Pharmacokinet; 2013 Apr; 52(4):289-301. PubMed ID: 23420517
[TBL] [Abstract][Full Text] [Related]
19. Area under the curve achievement of once daily tobramycin in children with cystic fibrosis during clinical care.
Brockmeyer JM; Wise RT; Burgener EB; Milla C; Frymoyer A
Pediatr Pulmonol; 2020 Dec; 55(12):3343-3350. PubMed ID: 32827334
[TBL] [Abstract][Full Text] [Related]
20. Effects of CFTR modulators on pharmacokinetics of tobramycin during acute pulmonary exacerbations in the pediatric cystic fibrosis population.
Albright JC; Houck AP; Pettit RS
Pediatr Pulmonol; 2020 Oct; 55(10):2662-2666. PubMed ID: 32568427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
